From: Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review
Author | Year | Phase | Disease stage | n | RT dose | Conc. CHT | Adj. CHT | pCR rate (%) | Downst | Tox gr.3+ | Postop. c |
---|---|---|---|---|---|---|---|---|---|---|---|
Crane [59] | 2010 | II | T3 N0-1 | 25 | 50.4 | Cap + Bev | rec | 32 | 84%7 | 4% | 12%9 |
Willett [60] | 2010 | I/II | T3/4 | 32 | 50.4 | 5-FU ci + Bev | rec | 16 | n.r | n.r | n.r |
Kourkourakis [61] | 2010 | II | T3 or N+ | 19 | 34 4 | Cap + Bev + Ami | Cap | 37 | n.r | n.r | 5% |
Liang [62] | 2011 | II | T3/4 or N+ | 28 | 45 | FOLFOX + Bev | n.s | 25 | n.r | n.r | n.r |
Velenik [63] | 2011 | II | T3/4 or N+ | 61 | 50.4 | Cap + Bev | Cap | 13 | 74%7 | n.r | 10%9 |
Di Petrillo [64] | 2012 | II | T3/4 or N+ | 26 | 50.4 | 5-FU ci + Ox + Bev5 | rec | 20 | n.r | 76% | n.r |
Gasparini [65] | 2012 | II | T3/4 or T2N+ | 43 | 50.4 | Cap + Bev | 5-FU/LV ± Bev | 14 | n.r | n.r | 8% |
Resch [66] | 2012 | II | T3 | 8 | 45 | Cap + Bev | dis | 25 | n.r | 50%8 | 25% |
Kennecke [67] | 2012 | II | T3/4 or N2 | 42 | 50.4 | Cap + Ox + Bev | n.s | 18 | n.r | n.r | 11%9 |
Spigel [68]1 | 2012 | II | T3/4 or N+ | 35 | 50.4 | 5-FU + Bev | FOLFOX + Bev | 29 | n.r | n.r | n.r |
Landry [69] | 2013 | II | T3/4 | 53 | 50.4 | Cap + Ox + Bev | FOLFOX + Bev | 17 | 59%7 | 72% | 6%9,10 |
Dellas [70] | 2013 | II | T3/43 | 70 | 50.4 | Cap + Ox + Bev | Cap | 17 | n.r | 11% | 16% |
Wang [71] | 2014 | II | T3/4 or N+ | 12 | 45 | FOLFOX + Bev | n.s | 33 | n.r | 25% | 0% |
Borg [72]2 | 2014 | II | T3 | 45 | 45 | 5-FU ci + Bev | n.s | 11 | n.r | 20% | 20% |
Garcia [73] | 2015 | II | T3/4 | 43 | 45 | Cap + Bev | Cap or CAPOX11 | 8 | 78%7 | n.r | n.r |
Sadahiro [74] | 2015 | II | T3/4 or N+ | 52 | 45 | S-1 + Bev | S-1 | 19 | 71%7 | 2% | 29% |
Salazar [75] | 2015 | II, rand | T3/4 or N+ | 90 | 45 | Cap + Bev | n.s | 16 | 73%7 | 16% | 16% |
45 | Cap | 11 | 78%7 | 13% | 7% | ||||||
Maeda [76] | 2018 | II | T3/4 or N+ | 25 | 50.4 | Cap + Bev | Cap | 16 | n.r | 0% | n.r |
Yu [77] | 2018 | II | T3/4 or N+ | 45 | 50 | Cap + Ox + Bev6 | XELOX → Cap | 40 | n.r | 20% | 13%9 |